Table 1.

Clinical information of patients with suspected pulmonary thromboembolism

Patient	Gender	Age (years)	BMI (kg/m2)	Symptom	Initial diagnosis	Initial treatment	D-dimer (mg/L)	NT-proBNP (pg/mL)	Duration* (months)	Surgery	Pathologic diagnosis
1	Male	50	24	Hemoptysis, chest pain, dyspnea	Acute PTE	Anticoagulation	0.42	153.2	8	PEA	Organized thrombus
2	Female	46	20	Chest pain, weight-loss	Acute PTE	Anticoagulation	0.37	241.7	3	PEA	Organized thrombus
3	Male	47	22	Chest pain, hemoptysis	Acute PTE	Thrombolysis	0.25	2128.2	25	PEA	Organized thrombus
4	Female	59	21	Dyspnea	Chronic PTE	Anticoagulation	0.14	2955	20	PEA	Organized thrombus
5	Female	40	22	Dyspnea, weight-loss	Chronic PTE	Anticoagulation	0.63	729.3	24	PEA	Organized thrombus
6	Female	69	22	Chest pain, dyspnea, hemoptysis	Acute PTE	Anticoagulation	0.51	2959	2	TCSB	Intimal sarcoma
7	Male	47	25	Chest pain	Acute PTE	Anticoagulation	2.39	161.2	10	TCSB	Intimal sarcoma
8	Male	45	22	Cough, dyspnea, fever	Acute PTE	Anticoagulation	0.23	58	10	PEC	Fibrosarcoma
9	Male	30	22	Chest pain, hemoptysis, fever	Acute PTE	Anticoagulation	0.55	137	9	PEC	Intimal sarcoma
10	Male	59	22	Cough, chest pain, dyspnea	Acute PTE	Anticoagulation	0.21	374.3	3	TCSB	Intimal sarcoma
11	Male	36	21	Cough, hemoptysis, chest pain, weight-loss	Acute PTE	Thrombolysis	9.47	2384	9	PEC	Fibrosarcoma

BMI, body mass index; NT-proBNP, N-terminal pro-brain natriuretic peptide; PTE, pulmonary thromboembolism; PEA, pulmonary endarterectomy; TCSB, transvenous catheter suction biopsy; PEC, pneumonectomy.

^*duration was defined as the time between the initial symptoms and surgery.